Where will the main commercial opportunities lie in the treatment of pain from the present onwards? Our new pharma report explains in depth, giving you the answers that you require.
There remain many unmet therapeutic needs in the treatment of pain, as well as high demand for analgesic treatments worldwide. For several types of pain, including conditions such as diabetic neuropathy and sciatica, there are currently few treatments. Furthermore, the pain sector is associated with side effects. Novel compounds that demonstrate improved safety profiles - combined with high efficacies - have the potential to gain significant market shares from 2009 onwards. At the same time, high regulatory hurdles - in particular those following the Vioxx withdrawal - could restrict market entry. Nevertheless, there remain high potential revenues to be made in this sector from 2009 to 2024, as our new report explains.
Continued high prevalence of pain worldwide, driven by an increase in the many disorders with pain as a symptom, drives the market. Furthermore, intensive R&D - with a solid current pipeline - will make the analgesics market dynamic and commercially promising in the years ahead. There is also rapidly-increasing demand for pain treatments in developing countries. Our new report - The Global Analgesics Market 2009-2024 – explains how this market will develop, and where the main opportunities will lie during our forecast period.
This report addresses the following therapeutic categories in detail:
• Non-narcotics and anti-pyretics
• Narcotics
• Anti-rheumatic drugs
• Anti-migraine drugs
• Anti-epileptic drugs
• Local anaesthetics.
The Global Analgesics Market 2009-2024 provides detailed forecasts for all six categories, as well as for individual products in each category. What types of therapeutic agents are likely to enter the market from 2009 onwards, and will they hold the potential to dominate? Where do the main opportunities lie, and what are the principal threats in this market area? This report will provide you with the analytical information that you need to understand current trends and future directions in the global analgesics market. We discuss prospects for the following products in detail (by category):
• Non-narcotics and anti-pyretics
- Tylenol
- Advil
- Aspirin Bayer
- Panadol
• Narcotics
- Oxycontin
- Duragesic
- Fentanyl Myla
• Anti-rheumatic drugs
- Celebrex
- Voltaren
• Anti-migraine drugs
- Imigran
- Maxalt
• Anti-epileptic drugs
- Lyrica
• Local anaesthetics
- Lidoderm
Novel therapeutics and other developments - such as Rx/Dx strategies, monoclonal antibodies and anti-abuse technologies - are included in the pipeline sections of this report.
Comprehensive analysis of the market area
The Global Analgesics Market 2009-2024 examines this market sector critically, through a comprehensive review of information sources, including consultations with relevant experts. There are over 60+ tables and figures plus comprehensive expert interviews. This report provides detailed sales forecasts, discussions of pipeline developments and relevant commercial drivers and restraints. Sources used include commercial databases, industry news, published reports, policy documents and economic research. Importantly, we apply rigorous financial forecasting, qualitative analyses and the assessments of unmet needs. The result is a comprehensive market- and industry-centred report with detailed analysis and informed opinion to benefit your work.
Why you should buy The Global Analgesics Market 2009-2024
In this report you will receive the following benefits, in particular:
• You will assess the current market for analgesic therapeutics
• You will review the overall analgesic therapeutics market, including a global sales forecast for 2009 to 2024
• You will receive sales forecasts for analgesic submarkets from 2009 to 2024, with detailed discussions
• You will receive sales forecasts for leading products from 2009 to 2024, with detailed discussions of market potential and competition
• You will receive sales forecasts for leading geographical markets from 2009 to 2024, with discussions
• You will examine commercial drivers and restraints in depth
• You will discover the most-exciting pipeline developments in the sector, with informed commentary to give you foresight
• You will discover expert opinions from our original survey of the sector, with full interview transcripts provided.
You can obtain this report today
Nobody with an interest in the analgesics field can afford to overlook this new market study. We predict that total revenues in the analgesics market will increase throughout the forecast period 2009 to 2024. Continued and increasing prevalence of the conditions, coupled with high associated economic costs, give this market great potential from 2009 onwards. Do you want to know more? You can stay ahead by ordering this report today.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
